170
Participants
Start Date
April 6, 2021
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2026
standard of care
patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
radiotherapy + standard of care
"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
RECRUITING
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
RECRUITING
Wei-Fang Yang, Taizhou
Liaoning Cancer Hospital & Institute
OTHER
Wuhan University
OTHER
China-Japan Union Hospital, Jilin University
OTHER
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
OTHER
West China Hospital
OTHER
Shanxi Province Cancer Hospital
OTHER
Peking Union Medical College Hospital
OTHER
Chinese Academy of Medical Sciences
OTHER